This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Cascinu, S. Articles by Catalano, G. Search for Related Content PubMed PubMed Citation Articles by Cascinu, S. Articles by Catalano, G.

Cytokinetic Effects of Interferon in Colorectal Cancer Tumors: Implications in the Design of the Interferon/5-Fluorouracil Combinations

Servizio di Oncologia [S. C., E. D. F., A. F., G. C.], Laboratorio Analisi [C. G., M. A., M. B.], and Divisione di Chirurgia [G. F., F. L.], Ospedali Riuniti, P. le Cinelli 4, 61100 Pesaro, and Cattedra di Semeiotica Chirurgica, Università di Ancona, Ancona [Q. O., V. S.], Italy

Interferon (IFN) has been shown to enhance the cytotoxic effects of 5-fluorouracil (5FUra) in colorectal cancer, and clinical trials with this combination resulted in higher response rate with respect to 5FUra alone. IFN is generally administered s.c. three times a week. This prolonged exposure could determine a block of tumor cells in the G₀-G₁ phase of the cell cycle, thus rendering tumor cells insensitive to 5FUra, an S-phase specific agent. In order to verify the presence of this block, 21 operable colorectal cancer patients were treated with IFN-_2b at the dose of 3 megaunits every other day in the week before operation, while another 22 represented the control group. Samples of tumor tissue were taken at endoscopy and operation. [³H]Thymidine labeling index and flow cytometry were used to assess the S-phase fraction. In IFN treated patients, we found a significant statistical difference between the mean percentage of S-phase fractions evaluated either by labeling index (P = 0.00001) or by flow cytometry (P < 0.001). On the contrary, this difference was not present in the control group: labeling index, P = 0.06; flow cytometry, P = 0.08. Furthermore a significant increase in the G₀-G₁ phase of the cell cycle was found after IFN administration (P < 0.001) but not in the control group. Our results suggest that IFN reduces the S-phase fraction in colorectal cancer tumors. This action should be considered in the design of the 5FUra/IFN combination because it could decrease 5FUra activity, leading to a loss or a decrease in the advantage of 5FUra modulation by IFN.

¹ To whom requests for reprints should be addressed, at Servizio di Oncologia, Ospedali Riuniti. P. le Cinelli 4, 61100 Pesaro, Italy.

² Recipient of a grant from Associazione Italiana Ricerca Cancro (AIRC).

Received 6/ 9/93. Accepted 9/14/93.